ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Atopic
Dermatitis
AD
Eczema

Interventions

DRUG: ATI-045
DRUG: Placebo

Sponsor

Aclaris Therapeutics, Inc.